[go: up one dir, main page]

WO1999050637A8 - Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes - Google Patents

Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes

Info

Publication number
WO1999050637A8
WO1999050637A8 PCT/US1999/006615 US9906615W WO9950637A8 WO 1999050637 A8 WO1999050637 A8 WO 1999050637A8 US 9906615 W US9906615 W US 9906615W WO 9950637 A8 WO9950637 A8 WO 9950637A8
Authority
WO
WIPO (PCT)
Prior art keywords
complexes
useful
cells
analysis
making
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1999/006615
Other languages
English (en)
Other versions
WO1999050637A2 (fr
WO1999050637A3 (fr
Inventor
Pedro Romero
Rod Dunbar
Danila Valmori
Mikael Pittet
Daniel Speiser
Vincenzo Cerundolo
Graham Ogg
Jean-Charles Cerrotini
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ludwig Institute for Cancer Research Ltd
University of Oxford
Ludwig Cancer Research
Original Assignee
Ludwig Institute for Cancer Research Ltd
University of Oxford
Ludwig Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Institute for Cancer Research Ltd, University of Oxford, Ludwig Cancer Research filed Critical Ludwig Institute for Cancer Research Ltd
Priority to AU33654/99A priority Critical patent/AU3365499A/en
Publication of WO1999050637A2 publication Critical patent/WO1999050637A2/fr
Publication of WO1999050637A8 publication Critical patent/WO1999050637A8/fr
Publication of WO1999050637A3 publication Critical patent/WO1999050637A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention se rapporte à des complexes multicomposants qui sont utiles à l'analyse des lymphocytes T. Ces complexes contiennent au moins un premier et un second partenaire de liaison qui se lient l'un à l'autre. Le second partenaire de liaison s'accouple à une pluralité de complexes immuns qui comportent une molécule de CMH, une molécule de β2 microglobuline et un peptide. De préférence, il y a au moins quatre de ces complexes immuns par complexe multicomposant. Ces complexes peuvent servir à déterminer ou à isoler des lymphocytes T cytolytiques.
PCT/US1999/006615 1998-03-27 1999-03-25 Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes Ceased WO1999050637A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU33654/99A AU3365499A (en) 1998-03-27 1999-03-25 Isolated multimeric complexes useful in analysis of t cells, peptides useful in making the complexes, and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4985098A 1998-03-27 1998-03-27
US09/049,850 1998-03-27

Publications (3)

Publication Number Publication Date
WO1999050637A2 WO1999050637A2 (fr) 1999-10-07
WO1999050637A8 true WO1999050637A8 (fr) 2000-01-06
WO1999050637A3 WO1999050637A3 (fr) 2000-04-13

Family

ID=21962080

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/006615 Ceased WO1999050637A2 (fr) 1998-03-27 1999-03-25 Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes

Country Status (2)

Country Link
AU (1) AU3365499A (fr)
WO (1) WO1999050637A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
NZ331688A (en) 1996-03-28 2000-02-28 Univ Johns Hopkins Soluble divalent and multivalent heterodimeric analogs of proteins
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
FR2806727A1 (fr) * 2000-03-23 2001-09-28 Pf Medicament Molecule d'interet pharmaceutique comprotant en son extremite n-terminale un acide glutamique ou une glutamine sous forme de sel d'addition d'acide fort physiologiquement acceptable
AU2001271273A1 (en) * 2000-05-24 2001-12-03 Ludwig Institute For Cancer Research Multicomponent conjugates which bind to target molecules and stimulate cell lysis
CA2440474A1 (fr) 2001-04-05 2002-10-17 Virginia Mason Research Center Procedes de cartographie d'epitopes de la classe i du complexe majeur d'histocompatibilite, cmh, detection de lymphocytes t autoimmuns et d'antigenes, et traitement autoimmun.
WO2009003492A1 (fr) 2007-07-03 2009-01-08 Dako Denmark A/S Procédés améliorés pour produire, marquer et utiliser des multimères du cmh
US7892559B2 (en) * 2002-01-30 2011-02-22 Survac Aps Survivin-derived peptides and use thereof
US20040072262A1 (en) 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
EP1766393A4 (fr) * 2004-05-07 2008-06-18 Beckman Coulter Inc Système de formation de pont de complexes d'histocompatibilité principale pour détecter une lyse médiée par les lymphocytes t de cellules présentant des antigènes
EP2226332A1 (fr) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Épitopes de tuberculose par mycobacterium et ses procédés d'utilisation
EP2361930A3 (fr) 2007-03-26 2011-10-26 Dako Denmark A/S Multimeres du complexes peptide-cmh et leur utilisation dans des maladies infectieuses de borrelia
WO2009039854A2 (fr) 2007-09-27 2009-04-02 Dako Denmark A/S Multimères cmh dans le diagnostic, le vaccin et le traitement de la tuberculose
DK2254592T3 (da) 2008-02-28 2019-09-09 Dako Denmark As MHC-multimerer til Borrelia-diagnostik og sygdom
WO2010009735A2 (fr) 2008-07-23 2010-01-28 Dako Denmark A/S Analyse et réparation combinatoires
WO2010037402A1 (fr) 2008-10-02 2010-04-08 Dako Denmark A/S Vaccins moléculaires contre les maladies infectieuses
US11992518B2 (en) 2008-10-02 2024-05-28 Agilent Technologies, Inc. Molecular vaccines for infectious disease
US12258373B2 (en) 2018-12-17 2025-03-25 Immudex Aps Panel comprising Borrelia MHC multimers

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9404916B2 (en) 2008-09-20 2016-08-02 University College Cardiff Consultants Limited Use of a protein kinase inhibitor to detect immune cells, such as T cells

Also Published As

Publication number Publication date
WO1999050637A2 (fr) 1999-10-07
AU3365499A (en) 1999-10-18
WO1999050637A3 (fr) 2000-04-13

Similar Documents

Publication Publication Date Title
WO1999050637A8 (fr) Complexes multicomposants isoles servant a l'analyse des lymphocytes t, peptides utiles a la fabrication de ces complexes et utilisations de ces complexes
EP2360259A3 (fr) Peptides de la promyostatine et procedes d'utilisation de ces derniers
EP1526141A3 (fr) complexes majeurs d'histocompatibilite et leurs utilisations
EP2141243A3 (fr) Supports de protéine pour mimer des anticorps et d'autres protéines de liaison
EP3196213A3 (fr) Anticorps dirigés contre her-3 et leurs utilisations
ATE387458T1 (de) Fas-antigenbindender ligand
EP2284180A3 (fr) Peptides qui lient spécifiquement le récepteur HGF (CMET) et utilisations associées
NO20000086L (no) Chimert løselig interleukin-6-reseptor/ligandprotein, og analoger og anvendelser av dette
CA2413156A1 (fr) Vecteurs d'expression
HUP0301812A2 (hu) Átvizsgálási (screening) eljárás
CA2302147A1 (fr) Procedes d'analyse de proteines
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
EP1005539A4 (fr) PROTEINES IKK-$g(a), ACIDES NUCLEIQUES ET PROCEDES
WO1998057983A3 (fr) Proteine de mammifere de type facteur de croissance nerveuse
WO2004018619A3 (fr) Molecules du recepteur des lymphocytes t se liant a la proteine p53, et leurs utilisations
WO2001094949A3 (fr) Compositions solubles a base de cd1 et leurs utilisations
EP2292638A3 (fr) Peptides antigènes MAGE-C2 et leurs utilisations
WO2001085779A3 (fr) Complexes proteiques et dosages de criblage d'agents anticancereux
WO2004096156A3 (fr) Effecteur du recepteur tlr 9 et ses utilisations
EP0352228A3 (fr) Protéines
EP0372503A3 (fr) Peptides anticoagulants
WO2002026778A3 (fr) Peptides isoles se liant a des molecules hla-c et utilisations de ceux-ci
AU5924699A (en) Methods for identifying hot-spot residues of binding proteins and small compounds that bind to the same
EP0885959A3 (fr) Protéine Wnt-5b humaine
CA2112701A1 (fr) Polypeptides des proteines s et leur utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: C1

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: C1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase